Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment, with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Glucagon-like peptide-1 (GLP-1) receptor agonists ... "The availability of large-scale human genetic association data allows ...

The team has tested the technology on both mouse and human subjects. In both cases, the painting process resulted in almost half of the targeted antibodies successfully attaching to the GLP-1 receptor ...

Two undergraduate medicine students at University of Galway have led a major study examining how cardioprotective ...